TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population
For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?
A one-of-a-kind cancer care delivery research trial that offers young women with cancer an assessment of their goals for fertility and family planning to make the most of cancer treatment and preserve future reproductive health
This trial is comparing two common surveillance methods in people with at least one non-cancerous cyst in the pancreas, to measure which one leads to better outcomes. The study may also uncover findings that could predict the behavior of these cysts.